|

Daratumumab and Recombinant Human Hyaluronidase Clinical Trials

4 actively recruiting trials across 3 locations

▲ +3 trials since August 2026

Also known as: DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab and Hyaluronidase, Daratumumab and Hyaluronidase-fihj +12 more

Pipeline

Phase 1: 1Phase 2: 3

Top Sponsors

  • National Cancer Institute (NCI)2
  • Roswell Park Cancer Institute1
  • Eden Biltibo1

Indications

  • Cancer4
  • Recurrent Multiple Myeloma2
  • Refractory Multiple Myeloma2
  • Plasma Cell Leukemia1
  • Multiple Myeloma1

Buffalo, New York2 trials

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center

Phase 1
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Roswell Park Cancer Institute

Phase 2

Philadelphia, Pennsylvania1 trial

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

ECOG-ACRIN Cancer Research Group

Phase 2

Nashville, Tennessee1 trial

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Vanderbilt University Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.